Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00489840 · ClinicalTrials.gov registry record · Phase 1
Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate
A Phase 1 study of Chronic Central Serous Chorioretinopathy, sponsored by Manhattan Eye, Ear & Throat Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
- 2
- Study locations
NCT00489840: Completed Phase 1 study of Chronic Central Serous Chorioretinopathy, sponsored by Manhattan Eye, Ear & Throat Hospital.
NCT00489840 is a Phase 1 study of Chronic Central Serous Chorioretinopathy that has completed, run by Manhattan Eye, Ear & Throat Hospital. The registered enrollment target is 5 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00489840, a Phase 1 study of Chronic Central Serous Chorioretinopathy, has completed, sponsored by Manhattan Eye, Ear & Throat Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
- 2
- Study locations
Study Summary
Investigation to evaluate Anecortave Acetate in the treatment of chronic central serous chorioretinopathy
Conditions Studied
Interventions
- DRUG Anecortave Acetate Sterile suspension 15 mg
- DRUG Anecortave Acetate
Study Locations (2)
New York
- Manhattan Eye, ear & Throat Institute - New York
- Vitreous-Retina-Macula Consultants of New York,PC - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2007-05 |
| Phase | Phase 1 |
What the finished NCT00489840 record still lists
NCT00489840 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Chronic Central Serous Chorioretinopathy appearing as the primary indexed condition, and to 2 interventions - of which Anecortave Acetate Sterile suspension 15 mg is the first listed.
NCT00489840 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00489840 about?
NCT00489840 is a clinical study titled "Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate". Investigation to evaluate Anecortave Acetate in the treatment of chronic central serous chorioretinopathy
What is the current status of trial NCT00489840?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2007-05.
What conditions does trial NCT00489840 study?
This clinical trial studies the following conditions: Chronic Central Serous Chorioretinopathy.
What interventions are being tested in trial NCT00489840?
The interventions under investigation include: Anecortave Acetate Sterile suspension 15 mg (DRUG), Anecortave Acetate (DRUG).
Who is sponsoring clinical trial NCT00489840?
This trial is sponsored by Manhattan Eye, Ear & Throat Hospital, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00489840 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00489840's enrollment target sits among peer trials
5 1989th of 2000 higher than 6 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia